« Back
Home /
Aloxistatin

Aloxistatin

Item no.	HY-100229-10mM
Manufacturer	MedChem Express
CASRN	88321-09-9
Amount	10mM/1mL
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Neuroscience Aging & Neurological Disorders Protein Aggregation, Clearance & Misfolding Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.55
Formula	C17H30N2O5
Citations	[1]Doh-Ura K, et al. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol. 2000 May;74(10):4894-7.<br>[2]Konjar S, et al. Human and mouse perforin are processed in part through cleavage by the lysosomal cysteine proteinase cathepsin L. Immunology. 2010 Oct;131(2):257-67.<br>[3]Mullins SR, et al. Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins. Biol Chem. 2012 Dec;393(12):1405-16.<br>[4]Hook G, et al. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity. J Alzheimers Dis. 2011;26(2):387-408.<br>[5]Cheng XW, et al. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol. 2008 Aug;173(2):358-69.<br>[6]Ji Yeun Kim, et al. Safe, High-Throughput Screening of Natural Compounds of MERS-CoV Entry Inhibitors Using a Pseudovirus Expressing MERS-CoV Spike Protein. Int J Antimicrob Agents. 2018 Nov;52(5):730-732.
Smiles	O=C([C@H]1O[C@@H]1C(N[C@H](C(NCCC(C)C)=O)CC(C)C)=O)OCC
ECLASS 5.1	30220300
ECLASS 6.1	30220300
ECLASS 8.0	32160605
ECLASS 9.0	32160605
ECLASS 10.0.1	32160490
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	E64d; E64c ethyl ester
Available
Product Description	Aloxistatin (E64d) is a cell-permeable and irreversible broad-spectrum cysteine protease inhibitor. Aloxistatin (E64d) exhibits entry-blocking effect for MERS-CoV.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Neuroscience-Neurodegeneration
MolecularWeight	342.43
Clinical_Information	Phase 3
Manufacturers Research Area	Neurological Disease
Solubility	DMSO : 125 mg/mL (ultrasonic)\|Ethanol : ≥ 33.33 mg/mL
Manufacturers Target	Cathepsin; SARS-CoV
Pathway	Anti-infection; Metabolic Enzyme/Protease

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-100229-10mM-safety-datasheet.pdf